Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name RPLP0P2
   Synonyms RPLP0P2, RPLP0L2, RPLP0_3_1146
   Region GRCh38_11:61615036-61639449    Sequence
   Ensembl ENSG00000243742
   RefSeq NA
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name lung adenocarcinoma
   ICD-0-3 C34  M8140/3
   Methods qPCR, Cell transfection, Cell migration and invasion assay etc.
   Sample LAD tissues, cell lines (SPCA-1, NCI-H1299, A549, NCI-H441, LTEP-a2)
   Expression Pattern down-regulated
   Function Description

We found that RPLP0P2 expression was lower while LRRC10B mRNA level was higher in LAD than NT by qPCR. The expression of RPLP0P2 in lymph node metastasis of LAD group was significantly lower than LAD without lymph node metastasis group. Survival analysis showed that survival time of high expression of RPLP0P2 was significantly longer than low RPLP0P2 level in LAD patients. After RPLP0P2 was overexpressed, the proliferation rate, adhesion ability, S phase and G2/M phase cells and LRRC10B mRNA significantly reduced, while apoptosis and G0/G1 phase cells obviously increased, but migration ability and invasion did not significantly change.

   Pubmed ID 27460542
   Year 2016
   Title Low expression lncRNA RPLP0P2 is associated with poor prognosis and decreased cell proliferation and adhesion ability in lung adenocarcinoma.
   External Links
   Links for  RPLP0P2 GenBank       HGNC       lncrnadb       Noncode
   Links for  lung adenocarcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.